Press Room

CPHI China 2025

Start
Tuesday, June 24, 2025 - 09:00
End
Thursday, June 26, 2025 - 18:00
Location: Shanghai, China
Booth Number: E1C51



Hovione is exhibiting at CPHI China, Asia’s premier pharma event, bringing together suppliers and buyers from the entire pharmaceutical supply chain. Global pharma experts gather in Shanghai to network, inspire innovation and drive change.

If you are facing solubility and bioavailability challenges or just curious about new technologies that address your small molecule and biologics needs, meet the Hovione team at booth # E1C51 and learn more about our leadership in Spray Drying. With the largest number of commercial projects, the best science and engineering, the largest capacity, and the most experienced team, Hovione can take your project from development to market like no one else.

We look forward to seeing you at CPHI China. 

Schedule a meeting today.

 

schedule a meeting

Also in the Press Room

See All

Hovione is bringing momentum to the intranasal field after announcing that its lead single-use nasal dry powder device, developed in collaboration with Industrial Design Consultancy Ltd (IDC), is now available for commercial partnerships. The milestone marks the transition from prototype to a fully integrated intranasal drug delivery platform that spans Hovione’s end-to-end partnership capabilities–from API synthesis through advanced formulation and particle engineering to drug product manufacturing, including device supply and advanced analytical tools for nasal performance characterization. The platform’s single-use device is designed to be manufacturable at scale and to leverage existing advanced particle engineering and drug product manufacturing capabilities, a practical advantage that can shorten timelines to clinic and commercialization while reducing development risk and cost. The device’s patented mechanism supports targeted nasal deposition, including access to the upper olfactory region. This enables rapid systemic absorption and potential nose-to-brain delivery pathways that are increasingly important for CNS and emergency-use indications. Beyond the single-use format, Hovione and IDC are advancing a multi-dose variant to broaden applicability across dosing regimens and therapeutic areas. The collaboration is backed by an intellectual property portfolio and initial patent grants, positioning the platform as a turnkey option for pharma partners seeking a single integrated supplier for both drug substance and device. This development arrives as intranasal delivery gains traction for systemic, CNS and rapid-onset therapies. This is precisely the focus of the upcoming 4th Nasal Formulation & Delivery Summit, for which Hovione is a key sponsor. The annual summit unites formulation, delivery and product development leaders to tackle drug-device compatibility, translational preclinical models, and strategies for scalable, regulatory-ready intranasal programs. Hovione’s recent progress will be highly relevant to attendees looking to de-risk nose-to-brain and systemic intranasal programs. Read the full article at News-Medical.net    

Press Clipping

Hovione advances intranasal drug delivery with commercial-ready dry powder platform ahead of 4th Nasal Formulation & Delivery Summit

Jun 01, 2026